Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Pazopanib
Drug ID BADD_D01687
Description Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Indications and Usage Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
Marketing Status approved
ATC Code L01EX03
DrugBank ID DB06589
KEGG ID D05380
MeSH ID C516667
PubChem ID 10113978
TTD Drug ID Not Available
NDC Product Code Not Available
UNII 7RN5DR86CK
Synonyms pazopanib | GW 786034B | GW786034B | GW-786034B | GW 780604 | GW780604 | GW-780604 | Votrient
Chemical Information
Molecular Formula C21H23N7O2S
CAS Registry Number 444731-52-6
SMILES CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Metastases to adrenals05.01.04.007; 16.22.02.0120.000280%-
Metastases to bone15.09.03.006; 16.22.02.0050.001500%-
Metastases to kidney16.22.02.017; 20.01.04.0100.000224%-
Metastases to lymph nodes01.09.01.015; 16.22.02.0060.000582%-
Metastases to pleura16.22.02.022; 22.05.04.0020.000168%-
Metastases to skin16.22.02.023; 23.07.04.0260.000168%-
Metastases to the mediastinum16.22.02.027; 22.09.03.0090.000112%-
Pneumothorax spontaneous22.05.02.0070.000224%-
Recurrent cancer16.16.01.0150.000414%-
Renal cancer recurrent16.08.02.007; 20.01.04.0130.000336%-
Renal cancer stage IV16.08.02.008; 20.01.04.0140.000112%-
Renal cell carcinoma stage IV16.08.02.010; 20.01.04.0160.000280%-
Renal haematoma12.01.05.006; 20.01.02.018; 24.07.07.0040.000112%-
Retroperitoneal cancer07.21.03.008; 16.13.04.0060.000112%-
Synovial sarcoma15.09.03.022; 16.33.01.0040.000448%-
Urinary bladder haemorrhage20.03.01.023; 24.07.01.0860.000302%-
Uterine leiomyosarcoma16.33.07.003; 21.07.02.0130.000224%-
Concomitant disease progression08.01.03.0640.000112%-
Terminal state08.01.03.0790.000280%-
Neck mass15.03.02.0070.000437%-
Metastases to pancreas07.21.09.005; 16.22.02.0200.000336%-
Renal cancer metastatic16.08.02.006; 20.01.04.0120.001567%-
Small intestinal haemorrhage07.12.03.002; 24.07.02.0190.000112%
Lymphangiosis carcinomatosa01.09.01.027; 16.22.02.009; 24.09.02.0070.000168%-
Adrenal mass05.01.03.0030.000112%-
Cardiac ventricular thrombosis02.11.01.008; 24.01.05.0060.000168%-
Dermatofibrosarcoma protuberans15.09.03.014; 16.33.03.0020.000112%-
Cell death08.03.03.003; 14.11.02.0050.000392%-
Gastrointestinal oedema07.11.01.0120.000224%-
Postrenal failure20.01.03.0210.000112%-
The 19th Page    First    Pre   19 20 21    Next   Last    Total 21 Pages